GEn-1124

Phase 2Small molecule

GGEn1E Lifesciences

GEn-1124 is one of 35 small molecule programs targeting Acute. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcuteRecruiting

OralRecruiting

AcutePhase 2

Recruiting

OralPhase 1

Recruiting

Competition

Competitive Landscape

50 competitors in Oral

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Phase 2

1 2

Marinol

Jazz Pharmaceuticals

Phase 1

2 3

GTX-104

GGrace Therapeutics Inc.

Phase 3

1 4

SHR-3167

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

1 5

GEn-1124

GGEn1E Lifesciences

Phase 2

1 6

Nubain

AAultman Health Foundation

Preclinical

1 7

Pitressin

AAultman Health Foundation

Preclinical

1 8

DRSP/EE

Vertex Pharmaceuticals

Phase 1

1 9

VX-407

Vertex Pharmaceuticals

Phase 1

1 10

AB-101

AArtiva Biotherapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Acute

NCT05795465

Clinical

Trials by Indication[1]

Oral1 trial

A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects

Recruiting·GGEn1E Lifesciences·Phase 1·NCT07185113·6 enrolled

Acute1 trial

A Phase 2, Two-Part Study to Evaluate the Safety and Tolerability of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

Recruiting·GGEn1E Lifesciences·Phase 2·NCT05795465·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GEn-1124. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GEn-1124 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GEn-1124. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GEn1E Lifesciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGEn1E Lifesciences

GEn-1124

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Oral1 trial

Acute1 trial

References

Drug Info

Quick Facts

Related News